Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Gregory M. Videtic MD CM
The rate of 1-year grade 3 or higher adverse events definitely, probably, or possibly related to treatment
Data for this trial is being collected via the NRG/RTOG Data Center.
Medically inoperable, biopsy proven early stage T1, T2 (< 5 cm) NSCLC patients; clinically node negative by PET, with peripherally located tumors (> 2 cm in all directions around the proximal bronchial tree)
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.